Journal article

In Drosophila, RhoGEF2 cooperates with activated Ras in tumorigenesis through a pathway involving Rho1-Rok-Myosin-II and JNK signalling

Peytee Khoo, Kirsten Allan, Lee Willoughby, Anthony M Brumby, Helena E Richardson

DISEASE MODELS & MECHANISMS | COMPANY BIOLOGISTS LTD | Published : 2013

Abstract

The Ras oncogene contributes to ≈ 30% of human cancers, but alone is not sufficient for tumorigenesis. In a Drosophila screen for oncogenes that cooperate with an activated allele of Ras (Ras(ACT)) to promote tissue overgrowth and invasion, we identified the GTP exchange factor RhoGEF2, an activator of Rho-family signalling. Here, we show that RhoGEF2 also cooperates with an activated allele of a downstream effector of Ras, Raf (Raf(GOF)). We dissect the downstream pathways through which RhoGEF2 cooperates with Ras(ACT) (and Raf(GOF)), and show that RhoGEF2 requires Rho1, but not Rac, for tumorigenesis. Furthermore, of the Rho1 effectors, we show that RhoGEF2 + Ras (Raf)-mediated tumorigenes..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Health & Medical Research (NHMRC)


Funding Acknowledgements

This work was supported by the National Health & Medical Research (NHMRC) grants 350369 and 400211, The Oncology Childhood Foundation (OCF), and funds from the Peter MacCallum Cancer Centre (PMCC) to H. E. R. P. K. was supported by an Australian Postgraduate Award, K. A. from the OCF, L. W. from the PMCC and A. M. B. from NHMRC 350396 and 509051 grants, and H. E. R. by a NHMRC Senior Research Fellowship.